Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell...

Area of Science:

• Hematology
• Transplantation Immunology
• Oncology

Background:

• Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes have improved, but data on non-remission cases are limited.
• Understanding factors influencing outcomes in non-remission allo-HCT is crucial for patient care.

Purpose of the Study:

• To analyze trends in non-relapse mortality (NRM) and causes of death after allo-HCT in acute leukemia patients not in remission.
• To evaluate the impact of evolving transplant modalities on allo-HCT outcomes.

Main Methods:

• Analysis of a nationwide transplant registry database covering 3308 acute leukemia patients in non-remission.
• Comparison of NRM incidence and causes across three consecutive four-year periods (1997-2008).

Main Results:

• A significant decrease in NRM was observed in the 2005-2008 period compared to 1997-2000 (HR 0.65).
• Overall mortality also significantly decreased in 2005-2008 (HR 0.85).
• Reduced deaths from graft-versus-host disease (GVHD) and infection contributed to lower NRM, potentially due to improved HLA matching.

Conclusions:

• Effective prevention of transplant-related complications, such as GVHD and infection, is essential for improving survival in non-remission allo-HCT.
• Improvements in transplant strategies have positively impacted outcomes for these high-risk patients.